What is Avinger?
Headquartered in Redwood City, California, Avinger specializes in the design and manufacture of sophisticated catheter-based systems that integrate optical coherence tomography (OCT) for real-time intravascular imaging. By providing physicians with high-resolution visual feedback, the company's lumivascular platform—including the Ocelot, Tigereye, and Pantheris product lines—enables precise arterial plaque removal and blockage penetration. Avinger serves a critical niche within the interventional cardiology and vascular surgery sectors, primarily operating across the United States and Germany to improve patient outcomes in complex PAD procedures.
How much funding has Avinger raised?
Avinger has raised a total of $125M across 6 funding rounds:
Debt
$10.5M
Stock Offering
$65M
Debt
$33M
Debt
$10M
Stock Offering
$4.5M
Debt
$2M
Debt (2013): $10.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $65M, investors not publicly disclosed
Debt (2015): $33M supported by CRG
Debt (2016): $10M featuring CRG LP
Stock Issuance/Offering (2019): $4.5M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Key Investors in Avinger
CRG LP
CR Group L.P. is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and equity investments across life sciences and healthcare services.
Undisclosed Investors
Undisclosed Investors
What's next for Avinger?
Following this major strategic investment, Avinger is positioned to accelerate the development of its pipeline, most notably the IMAGE-BTK program designed for below-the-knee lesion treatment. As the company scales its commercial operations, the focus remains on expanding the clinical adoption of its image-guided atherectomy devices. By leveraging its established lumivascular infrastructure, Avinger aims to capture further market share in the global vascular intervention landscape, ensuring that its technological advancements translate into sustainable long-term growth and improved standards of care for patients suffering from chronic arterial conditions.
See full Avinger company page
